Mirum’s Atebrioz reduces bone lesion volume in FOP trial in children aged 6 to under 12
MIRM•Mirum Pharmaceuticals reported positive pivotal PROGRESS trial results for Atebrioz in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. Treatment reduced abnormal bone formation versus placebo, improved joint mobility and prevented new lesions over 24 weeks.
1. Trial results
In the 24-week study, Atebrioz reduced abnormal bone formation versus placebo, improved joint mobility and prevented new lesions in children aged 6 to under 12. Mirum plans to submit a supplemental application in the first half of 2027 to seek approval for this age group; the company said full results showed no new safety signals and will be presented at an upcoming medical meeting.
